Drug intelligence / Profile preview

HPB2

Development stage: Preclinical
Modality: Small Molecules

Overview

HPB2 is a synthetic small molecule ligand for the orphan nuclear receptor estrogen-related receptor gamma (ERRγ). It has been shown to ameliorate depression-like behavior and enhance adult neurogenesis in young female LRRK2-G2019S mice, a model for Parkinson's disease. Its mechanism involves increasing the number of spines and dendrites in the hippocampal dentate gyrus and upregulating brain-derived neurotrophic factor (BDNF)/tropomyosin receptor kinase B (TrkB) signaling, which are crucial for neurogenesis.

Other names: (E)-4-hydroxy-N'-(4-(phenylethynyl)benzylidene)benzohydrazide

Targets

ESRRG (Estrogen-related receptor gamma)

Beyond the preview

Go deeper on HPB2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HPB2.

Explore the full profile